Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.

Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience. Dose Response. 2019 Oct-Dec;17(4):1559325819887068 Authors: O'Farrell E, Bird B, Murphy C PMID: 31802992 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31802992?dopt=Abstract

Source: Dose Response - September 30, 2019 Category: Drugs & Pharmacology Authors: O'Farrell E, Bird B, Murphy C Tags: Dose Response Source Type: research

More News: Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology